Medical technology company Sigyn Therapeutics Inc (OTCMKTS:SIGY) saw its stock trade within a range on Tuesday but at the same time it ought to be noted that the company was actually in the news. It may be a good idea for investors to consider taking a look at the announcement made by the company yesterday.
On Tuesday, SIGY stock ended flat at $0.38 with 1K shares, compared to its average volume of 1.3K shares. The stock moved within a range of $0.3799 – 0.3799 after opening trade at $0.3799.
Sigyn Therapeutics Appoints Donald J. Hillebrand, M.D. to its Scientific Advisory Board
Sigyn announced on Tuesday that it had made a new appointment to its Scientific Advisory Board in the form of Donald J Hilebrand, M.D. It is a key appointment from the company considering the fact that Hilebrand is currently employed as the associate medical director of Liver Transplantation at Saint Luke’s Hospital of Kansas City and Associate Professor of Medicine at the University of Missouri Kansas City.
As far as Hepatology and Liver Transplantation is concerned, he is a recognised leader. He has served in a wide range of roles over the course of his illustrious career and his addition to the Scientific Advisory Board could be a significant boost for Sigyn Therapeutics. At this point in time, it may be a good idea for investors to consider adding the stock to their watch lists and keep an eye on the developments.